Kymera Therapeutics

OverviewSuggest Edit

Kymera Therapeutics is a biotechnology company aimed to create medicines for patients with previously untreatable diseases. The company specializes in the field of targeted protein degradation (TPD) accessing the body’s innate protein recycling machinery to degrade rather than inhibit dysregulated, disease-causing proteins. Its proprietary integrated degradation platform, Pegasus, consists of informatics-driven target identification, novel E3 ligases, proprietary ternary complex predictive modeling capabilities and degradation tools.

TypePrivate
Founded2017
HQCambridge, US
Websitekymeratx.com

Latest Updates

Employees (est.) (Aug 2020)58
Cybersecurity ratingAMore

Key People/Management at Kymera Therapeutics

Nello Mainolfi

Nello Mainolfi

Founder, President, Chief Executive Officer & Director
Jared Gollob

Jared Gollob

Chief Medical Officer
Bruce Jacobs

Bruce Jacobs

Chief Financial Officer
Paige Cochran

Paige Cochran

VP, Human Resources
Show more

Kymera Therapeutics Office Locations

Kymera Therapeutics has an office in Cambridge
Cambridge, US (HQ)
300 Tech Square, 300 Technology Square 2nd Floor
Show all (1)

Kymera Therapeutics Financials and Metrics

Summary Metrics

Kymera Therapeutics's latest funding round in March 2020 was reported to be $102 m. In total, Kymera Therapeutics has raised $197 m
Show all financial metrics

Kymera Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Kymera Therapeutics Online and Social Media Presence

Embed Graph

Kymera Therapeutics News and Updates

Kymera Therapeutics Announces $102 Million Series C Financing to Advance its Protein Degrader Pipeline and Platform

CAMBRIDGE, Mass., March 12, 2020 /PRNewswire/ -- Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, today announced the closing of a $102 million Series C financing. The round was led by...

VC-backed Kymera Therapeutics appoints president and CFO

Cambridge, Massachusetts-based Kymera Therapeutics Inc, a biotechnology company, has named Dr. Nello Mainolfi as president and Bruce Jacobs as chief financial officer. Kymera's backers include 6 Dimensions Capital, Bessemer Venture Partners and Pfizer Ventures.

Kymera Therapeutics Announces $65 Million Series B Financing to Advance Pipeline of Targeted Protein Degraders in Oncology and Immunology

CAMBRIDGE, Mass., Nov. 13, 2018 /PRNewswire/ -- Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create breakthrough medicines for patients, announced today that it has completed a $65 million Series B financing. The financing will support the...

Kymera Therapeutics Blogs

Kymera Therapeutics to Present Preclinical Data Demonstrating Potent Antitumor Activity by a Selective STAT3 Degrader in Hematologic Malignancies at the American Society of Hematology Annual Meeting

Cambridge, Mass. (December 9, 2019) – Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to discover breakthrough medicines for patients, today announced the company will present new preclinical data showing the further characterization of novel, highly selecti…

Kymera Therapeutics Promotes Nello Mainolfi, PhD, to Chief Executive Officer

Cambridge, Mass. (November 20, 2019) – Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to discover breakthrough therapies for patients, today announced Kymera Co-founder, President and Chief Scientific Officer Nello Mainolfi, PhD, has been promoted to Presid…

Kymera Therapeutics to Present Preclinical Data on its First-in-Class IRAK4 Degraders Demonstrating Robust Inhibition of Inflammatory Responses and Superiority to IRAK4 Kinase Inhibitors

Data will be shared in an oral presentation at the 2019 American College of Rheumatology’s Annual Meeting in Atlanta Cambridge, Mass. (November 11, 2019) – Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to discover breakthrough medicines for patients, today…

Kymera Therapeutics to Present Preclinical Data Demonstrating the Potency and Antitumor Activity of a Selective STAT3 Degrader at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Cambridge, Mass. (October 17, 2019) – Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to discover breakthrough medicines for patients, today announced the company will present preclinical data showing the discovery and characterization of novel, selective, a…

Kymera Therapeutics is Named one of FierceBiotech’s “Fierce 15” Companies of 2019

Cambridge, Mass. (September 23, 2019) – Kymera Therapeutics Inc., a biotechnology company advancing the field of targeted protein degradation to create next generation medicines, today announced that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating i…

Kymera Therapeutics to Present New Preclinical Data for its First-In-Class Oral IRAK4 Degrader in MYD88-Mutant Lymphoma at Late-Breaking Session of the American Association for Cancer Research Annual Meeting

Poster #18, Late-Breaking Research: Experimental and Molecular Therapeutics (Session 2) to be Presented April 3, 2019 8:00 AM – 12:00 PM Cambridge, Mass. (March 29, 2019) – Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create breakthrough medicines for …
Show more

Kymera Therapeutics Frequently Asked Questions

  • When was Kymera Therapeutics founded?

    Kymera Therapeutics was founded in 2017.

  • Who are Kymera Therapeutics key executives?

    Kymera Therapeutics's key executives are Nello Mainolfi, Jared Gollob and Bruce Jacobs.

  • How many employees does Kymera Therapeutics have?

    Kymera Therapeutics has 58 employees.

  • Who are Kymera Therapeutics competitors?

    Competitors of Kymera Therapeutics include Urovant Sciences, IO Biotech and Breath Therapeutics.

  • Where is Kymera Therapeutics headquarters?

    Kymera Therapeutics headquarters is located at 300 Tech Square, 300 Technology Square 2nd Floor, Cambridge.

  • Where are Kymera Therapeutics offices?

    Kymera Therapeutics has an office in Cambridge.

  • How many offices does Kymera Therapeutics have?

    Kymera Therapeutics has 1 office.